AMG 317 / Amgen - LARVOL DELTA

Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study. (PubMed, Front Immunol) - "The search strategies were as follows: topic: TS=(biologic* OR "biologic* product*" OR "biologic* therap*" OR biotherapy* OR "biologic* agent*" OR Benralizumab OR "MEDI-563" OR Fasenra OR "BIW-8405" OR Dupilumab OR SAR231893 OR "SAR-231893" OR Dupixent OR REGN668 OR "REGN-668" OR Mepolizumab OR Bosatria OR "SB-240563" OR SB240563 OR Nucala OR Omalizumab OR Xolair OR Reslizumab OR "SCH-55700" OR SCH55700 OR "CEP-38072" OR CEP38072 OR Cinqair OR "DCP-835" OR DCP835 OR Tezspire OR "tezepelumab-ekko" OR "AMG-157" OR tezspire OR "MEDI-9929" OR "MEDI-19929" OR MEDI9929 OR Itepekimab OR "REGN-3500"OR REGN3500 OR "SAR-440340"OR SAR440340 OR Tralokinumab OR "CAT-354" OR Anrukinzumab OR "IMA-638" OR Lebrikizumab OR "RO-5490255"OR "RG-3637"OR "TNX-650"OR..."

Journal • Asthma • Cough • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

The Discovery and Development of AZD1402/PRS-060, an Inhaled, Potent and Selective Antagonist of the IL-4 Receptor Alpha (ERS 2018) - "...AZD1402/PRS-060 and dupilumab (IL-4R mAb) inhibited IL-4 and IL-13 induced proliferation of TF1 cells with similar potency (IC50 0.9 and 0.3 nM). In an Air Liquid Interface goblet cell differentiation assay induced by IL-13 stimulation, AZD1402/PRS-060 inhibited goblet cell metaplasia to a similar extent as AMG317 (IL-4R mAb) and pitrakinra...In the OVA model, inflammatory cell infiltration was reduced by 78% and TARC (CCL17) was reduced by 98% 48 h post challenge. AZD1402/PRS-060, potently inhibits IL-4 and IL-13 signalling in vitro and in vivo and based on these data and the proven benefit of targeting this receptor, AZD1402/PRS-060 has progressed into human clinical trials."

Asthma • Biosimilar • Immunology

Human lung tissue provides highly relevant data about efficacy of new anti-asthmatic drugs. (PubMed, PLoS One) - "Anti-inflammatory treatment with four different inhibitors acting either on the IL-13 ligand itself (anti-IL-13 antibody, similar to Lebrikizumab) or the IL-4Rα chain of the IL-13/IL-4 receptor complex (anti-IL-4Rα #1, similar to AMG 317, and #2, similar to REGN668) and #3 PRS-060 (a novel anticalin directed against this receptor) could significantly attenuate IL-13 induced inflammation. The results of this study show a more distinct efficacy than known from animals models and a clear discrepancy in AHR induction. Moreover, it allows a translational approach in inhibitor profiling in human lung tissue."

Biomarker • Clinical • Journal